A method for post-processing of finite element analyses to assess critical macroscopic voids

A method for post-processing of finite element analyses to assess critical macroscopic voids is presented. One single, global analysis of the structure or component is carried out and then post-processed. By using a template model and the same constitutive model as for the global model, a damage scaling function is defined once and then applied to the result from the global model. The result is a database with critical relative sizes for different void rotations at the integrations points in the global model

Do Security Breaches Matter to Consumers?

Online security has been an important topic in electronic business. However, even the best IT security infrastructures cannot assure that cyber-attacks and malicious intrusions can be prevented. Therefore, it is important to know what is to be done when a security breach occurs, and how it influences consumers’ perceptions and behaviors. Via a survey of 258 respondents, this paper makes a first attempt to identify the relationships among security breach announcements, consumers’ perceived risks (including performance risk, financial risk, time risk and privacy risk), company reputation and a consumer’s intention to transact. Our key findings and implications are discussed

Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence

Objectives: To reanalyse SmithKline Beecham’s Study 329 (published by Keller and colleagues in 2001), the primary objective of which was to compare the efficacy and safety of paroxetine and imipramine with placebo in the treatment of adolescents with unipolar major depression. The reanalysis under the restoring invisible and abandoned trials (RIAT) initiative was done to see whether access to and reanalysis of a full dataset from a randomised controlled trial would have clinically relevant implications for evidence based medicine. Design: Double blind randomised placebo controlled trial. Setting: 12 North American academic psychiatry centres, from 20 April 1994 to 15 February 1998. Participants: 275 adolescents with major depression of at least eight weeks in duration. Exclusion criteria included a range of comorbid psychiatric and medical disorders and suicidality. Interventions: Participants were randomised to eight weeks double blind treatment with paroxetine (20-40 mg), imipramine (200-300 mg), or placebo. Main outcome measures: The prespecified primary efficacy variables were change from baseline to the end of the eight week acute treatment phase in total Hamilton depression scale (HAM-D) score and the proportion of responders (HAM-D score ≤8 or ≥50% reduction in baseline HAM-D) at acute endpoint. Prespecified secondary outcomes were changes from baseline to endpoint in depression items in K-SADS-L, clinical global impression, autonomous functioning checklist, self-perception profile, and sickness impact scale; predictors of response; and number of patients who relapse during the maintenance phase. Adverse experiences were to be compared primarily by using descriptive statistics. No coding dictionary was prespecified. Results: The efficacy of paroxetine and imipramine was not statistically or clinically significantly different from placebo for any prespecified primary or secondary efficacy outcome. HAM-D scores decreased by 10.7 (least squares mean) (95% confidence interval 9.1 to 12.3), 9.0 (7.4 to 10.5), and 9.1 (7.5 to 10.7) points, respectively, for the paroxetine, imipramine and placebo groups (P=0.20). There were clinically significant increases in harms, including suicidal ideation and behaviour and other serious adverse events in the paroxetine group and cardiovascular problems in the imipramine group. Conclusions: Neither paroxetine nor high dose imipramine showed efficacy for major depression in adolescents, and there was an increase in harms with both drugs. Access to primary data from trials has important implications for both clinical practice and research, including that published conclusions about efficacy and safety should not be read as authoritative. The reanalysis of Study 329 illustrates the necessity of making primary trial data and protocols available to increase the rigour of the evidence base.Joanna Le Noury, John M Nardo, David Healy, Jon Jureidini, Melissa Raven, Catalin Tufanaru, Elia Abi-Jaoud

Study 329 continuation phase:Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression

OBJECTIVE: This is an analysis of the unpublished continuation phase of Study 329, the primary objective of which was to compare the efficacy and safety of paroxetine and imipramine with placebo in the treatment of adolescents with unipolar major depression. The objectives of the continuation phase were to assess safety and relapse rates in the longer term. The objective of this publication, under the Restoring Invisible and Abandoned Trials (RIAT) initiative, was to see whether access to and analysis of the previously unpublished dataset from the continuation phase of this randomized controlled trial would have clinically relevant implications for evidence-based medicine. METHODS: The study was an eight-week double-blind randomized placebo-controlled trial with a six month continuation phase. The setting was 12 North American academic psychiatry centres, from 20 April 1994 to 15 February 1998. 275 adolescents with major depression were originally enrolled in Study 329, with 190 completing the eight-week acute phase. Of these, 119 patients (43%) entered the six-month continuation phase (paroxetine n = 49; imipramine n = 39; placebo n = 31), in which participants were continued on their current treatment, blinded. As per the protocol, we have looked at rates of relapse (based on Hamilton Depression Scale scores) across both acute and continuation phases, and generated a safety profile for paroxetine and imipramine compared with placebo for up to six months. ANOVA testing (generalized linear model) using a model including effects of site, treatment and site x treatment interaction was applied. Otherwise we used only descriptive statistics. RESULTS: Of patients entering the continuation phase, 15 of 49 for paroxetine (31%), 12 of 39 for imipramine (31%) and 12 of 31 for placebo (39%) completed as responders. Across the study, 25 patients on paroxetine relapsed (41% of those showing an initial response), 15 on imipramine (26%), and 10 on placebo (21%). In the continuation and taper phases combined there were 211 adverse events in the paroxetine group, 147 on imipramine and 100 on placebo. The taper phase had a higher proportion of severe adverse events per week of exposure than the acute phase, with the continuation phase having the fewest events. CONCLUSIONS: The continuation phase did not offer support for longer-term efficacy of either paroxetine or imipramine. Relapse and adverse events on both active drugs open up the risks of a prescribing cascade. The previously largely unrecognised hazards of the taper phase have implications for prescribing practice and need further exploration

Scandal - A Facility For Elastic Neutron Scattering Studies in the 50-130 MeV Range

A facility for detection of scattered neutrons in the energy interval 50−130 MeV, SCANDAL (SCAttered Nucleon Detection AssembLy), is part of the standard detection system at the 20-180 MeV neutron beam facility of the The Svedberg Laboratory, Uppsala. It has primarily been used for studies of elastic neutron scattering, but it has been employed for (n,p) and (n,d) reaction experiments as well. Results of recent experiments are presented to illustrate the performance of the spectrometer. Recently, the facility has been upgraded to perform also (n,Xn') experiments. For this purpose, a new converter, CLODIA, has been developed and installed. Preliminary results of the commissioning of CLODIA will be presented

Decline in Iran’s groundwater recharge

Groundwater recharge feeds aquifers supplying fresh-water to a population over 80 million in Iran—a global hotspot for groundwater depletion. Using an extended database comprising abstractions from over one million groundwater wells, springs, and qanats, from 2002 to 2017, here we show a significant decline of around −3.8 mm/yr in the nationwide groundwater recharge. This decline is primarily attributed to unsustainable water and environmental resources management, exacerbated by decadal changes in climatic conditions. However, it is important to note that the former’s contribution outweighs the latter. Our results show the average annual amount of nationwide groundwater recharge (i.e., ~40 mm/yr) is more than the reported average annual runoff in Iran (i.e., ~32 mm/yr), suggesting the surface water is the main contributor to groundwater recharge. Such a decline in groundwater recharge could further exacerbate the already dire aquifer depletion situation in Iran, with devastating consequences for the country’s natural environment and socio-economic development